Birinci basamakta tiroid disfonksiyonuna yaklaşım ve tarama

Year 2019, Volume: 1 Issue: 3, 72 - 76, 01.07.2019

Baki Derhem

https://doi.org/10.38053/agtd.542706

Abstract

Fonksiyonel tiroid hastalıkları,
birinci basamakta sıklıkla görülen endokrin hastalıklardır. Genellikle,
hastaların ilk değerlendirmesini yapan ve biyokimyasal testlerini isteyen
birinci basamak hekimidir. Birçok fizyolojik süreçte tiroid hormonları rol
oynadığı için, tiroid disfonksiyonunda klinik bulgular ve belirtiler
nonspesifiktir. Tanı için laboratuvar testleri (özellikle TSH) gereklidir.
Primer hipotirodi tedavisinde levotiroksin (T4 hormonu) kullanılmaktadır ve
hasta hangi ilaçla tedaviye başlamışsa onunla devam etmesi gerektiği
savunulmaktadır. Türkiye’de tiroid fonksiyon anomalilerinin erken tanısı
amacıyla, ailesinde tiroid hastalığı bulunanlarda ilk karşılaşmada olmak üzere
35 yaşın üzerindeki bireylere beş yılda bir TSH bakılması önerilse de
semptomsuz hastalar ve gebe olmayanlar için tarama hala tartışmalıdır. Bu
derlemede, tedavi ayrıntılı olarak anlatılmamış olup, özellikle birinci basamak
hekimleri için, tiroid hastalıklarının tanısı ve taraması için yol gösterici
olması hedeflenmiştir.

Keywords

birinci basamak, tiroid hastalıkları, tiroid fonksiyon testleri

References

• 1. Thienpont LM, Uytfanghe KV, Poppe K, Velkeniers B. Determination of free thyroid hormones. Best Pract Res Clin Endocrinol Metab. 2013; 27: 689-700.
• 2. Carvalho GAD, Perez CLS, Ward LS. The clinical use of thyroid function tests. Arquivos Brasileiros de Endocrinologia & Metabologia. 2013; 57(3): 193-204.
• 3. Sheenan MT. Biochemical testing of the thyroid: TSH is the best and, oftentimes, only test needed–a review for primary care. Clinical medicine & research, 2016, 14.2: 83-92.
• 4. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. The Lancet Diabetes & Endocrinology. 2015; 3(10): 816-825.
• 5. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. Journal of Endocrinology 2010;205: 1-13.
• 6. Gaitonde DY, Rowley KD, Sweeney LB. "Hypothyroidism: an update." South African Family Practice 54.5 (2012): 384-390.
• 7. Spencer CA. Clinical utility and cost-effectiveness of sensitive thyro¬tropin assays in ambulatory and hospitalized patients. Mayo Clin Proc. 1988;63 (12): 1214-1222.
• 8. http://temd.org.tr/Kilavuzlar (Erişim tarihi: 19.03.2019)
• 9. Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 2012, 22.12: 1200-1235.
• 10. Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab. 2004;89: 4890-4987.
• 11. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twentyyear follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43: 55-68.
• 12. Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest. 2015;38: 283–94.
• 13. Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am. 2014; 32: 277–92.
• 14. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;37: 691–700.
• 15. Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ. 2014; 349:g5128.
• 16. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388: 906-918.
• 17. Canaris GJ, et al. The Colorado thyroid disease prevalence study. Archives of internal medicine, 2000, 160.4: 526-534.
• 18. Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0• 1 and 0• 4 mIU/l: a prospective study. Clinical endocrinology, 2010, 72.5: 685-688.
• 19. Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clinical endocrinology, 2008, 68.3: 491-492.
• 20. Blum MR, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. Jama, 2015, 313.20: 2055-2065.
• 21. Ross DS, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 2016, 26.10: 1343-1421.
• 22. DeGroot L, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 2012, 97.8: 2543-2565.
• 23. Yassa L, et al. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. The Journal of Clinical Endocrinology & Metabolism, 2010, 95.7: 3234-3241.
• 24. Stagnaro-Green A, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid, 2011, 21.10: 1081-1125.
• 25. Aile Hekimliği Uygulamasında Önerilen Periyodik Sağlık Muayeneleri ve Tarama Testleri. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, yayın no: 991, 2015.
• 26. LeFevre ML. Screening for thyroid dysfunction: US Preventive Services Task Force recommendation statement. Annals of internal medicine, 2015, 162.9: 641-650.